A carregar...

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014–2015 Northern Hemis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Vaccin Immunother
Main Authors: Mo, Zhaojun, Nong, Yi, Liu, Shuzhen, Shao, Ming, Liao, Xueyan, Go, Kerry, Lavis, Nathalie
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489275/
https://ncbi.nlm.nih.gov/pubmed/28301266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1285475
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!